![Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells | Nature Biotechnology Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells | Nature Biotechnology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41587-022-01637-z/MediaObjects/41587_2022_1637_Fig1_HTML.png)
Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells | Nature Biotechnology
![2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation](https://www.ahajournals.org/cms/asset/aa47aaff-b00d-4861-8f7f-e610c8679fd1/cir.0000000000001063.fig12.jpg)
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation
![2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation](https://www.ahajournals.org/cms/asset/25e072c4-19a0-427c-8b8e-3beed2b5268d/cir.0000000000001063.tab37.jpg)
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation
![PDF] Reference values for immunoglobulin kappa and lambda light chains and the kappa/lambda ratio in children's serum. | Semantic Scholar PDF] Reference values for immunoglobulin kappa and lambda light chains and the kappa/lambda ratio in children's serum. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/062e85a70c6f2d44975de989760becdae280cc49/3-Table2-1.png)
PDF] Reference values for immunoglobulin kappa and lambda light chains and the kappa/lambda ratio in children's serum. | Semantic Scholar
![PDF] Reference values for immunoglobulin kappa and lambda light chains and the kappa/lambda ratio in children's serum. | Semantic Scholar PDF] Reference values for immunoglobulin kappa and lambda light chains and the kappa/lambda ratio in children's serum. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/062e85a70c6f2d44975de989760becdae280cc49/2-Figure1-1.png)
PDF] Reference values for immunoglobulin kappa and lambda light chains and the kappa/lambda ratio in children's serum. | Semantic Scholar
![PDF] Reference values for immunoglobulin kappa and lambda light chains and the kappa/lambda ratio in children's serum. | Semantic Scholar PDF] Reference values for immunoglobulin kappa and lambda light chains and the kappa/lambda ratio in children's serum. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/062e85a70c6f2d44975de989760becdae280cc49/3-Figure2-1.png)
PDF] Reference values for immunoglobulin kappa and lambda light chains and the kappa/lambda ratio in children's serum. | Semantic Scholar
![PD-L1 Triggered by Binding eIF3I Contributes to the Amelioration of Diabetes-Associated Wound Healing Defects by Regulating IRS4 - ScienceDirect PD-L1 Triggered by Binding eIF3I Contributes to the Amelioration of Diabetes-Associated Wound Healing Defects by Regulating IRS4 - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0022202X21014603-gr6.jpg)
PD-L1 Triggered by Binding eIF3I Contributes to the Amelioration of Diabetes-Associated Wound Healing Defects by Regulating IRS4 - ScienceDirect
![Measurement of kappa (κ) and lambda (λ) light chains in free and total... | Download Scientific Diagram Measurement of kappa (κ) and lambda (λ) light chains in free and total... | Download Scientific Diagram](https://www.researchgate.net/publication/292707470/figure/fig2/AS:324773960798244@1454443555010/Measurement-of-kappa-k-and-lambda-l-light-chains-in-free-and-total-assays-Total.png)
Measurement of kappa (κ) and lambda (λ) light chains in free and total... | Download Scientific Diagram
![Measurement of kappa (κ) and lambda (λ) light chains in free and total... | Download Scientific Diagram Measurement of kappa (κ) and lambda (λ) light chains in free and total... | Download Scientific Diagram](https://www.researchgate.net/publication/292707470/figure/fig3/AS:324773969186832@1454443556723/Scatter-charts-showing-the-differences-in-sensitivity-between-the-FreeliteR-and-total_Q320.jpg)
Measurement of kappa (κ) and lambda (λ) light chains in free and total... | Download Scientific Diagram
![PDF] Reference values for immunoglobulin kappa and lambda light chains and the kappa/lambda ratio in children's serum. | Semantic Scholar PDF] Reference values for immunoglobulin kappa and lambda light chains and the kappa/lambda ratio in children's serum. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/062e85a70c6f2d44975de989760becdae280cc49/2-TableI-1.png)
PDF] Reference values for immunoglobulin kappa and lambda light chains and the kappa/lambda ratio in children's serum. | Semantic Scholar
![Frontiers | Higher Incidence of B Cell Malignancies in Primary Immunodeficiencies: A Combination of Intrinsic Genomic Instability and Exocytosis Defects at the Immunological Synapse Frontiers | Higher Incidence of B Cell Malignancies in Primary Immunodeficiencies: A Combination of Intrinsic Genomic Instability and Exocytosis Defects at the Immunological Synapse](https://www.frontiersin.org/files/Articles/581119/fimmu-11-581119-HTML/image_m/fimmu-11-581119-g001.jpg)
Frontiers | Higher Incidence of B Cell Malignancies in Primary Immunodeficiencies: A Combination of Intrinsic Genomic Instability and Exocytosis Defects at the Immunological Synapse
![2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation](https://www.ahajournals.org/cms/asset/2a7ac1f3-1f36-4f81-b4fb-de3ed78818a7/cir.0000000000001063.tab45.jpg)
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation
![2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation](https://www.ahajournals.org/cms/asset/4ee636b0-3ba0-416d-b804-1d074267b9dc/cir.0000000000001063.tab67.jpg)
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation
![2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation](https://www.ahajournals.org/cms/asset/2c2a3e2d-39cc-410f-a803-339551a8247f/cir.0000000000001063.tab71.jpg)